Clinical trial
Semaglutide as Treatment of Overweight and Obese Individuals to Reduce Atrial Fibrillation Burden
NCT05209165 is registered in ClinicalTrials.gov with San Francisco Veterans Affairs Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Semaglutide as Treatment of Overweight and Obese Individuals to Reduce Atrial Fibrillation Burden
- Lead sponsor
- San Francisco Veterans Affairs Medical Center
- Phase
- Phase 4
- Overall status
- Suspended
- Start date
- May 31, 2023
- Completion date
- May 31, 2028
- Enrollment
- 132 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.